Overview

Early Immunosuppressants in Crohn's Disease

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
Pluricentric randomized study comparing two therapeutic strategies at beginning of Crohn's disease: early immunosuppressants (prescription within the six first months following diagnosis) vs. conventional strategy (immunosuppressants given only in case of steroid failure, in a selected group of patients being at high risk of disabling course. The hypothesis is that immunosuppressants given early may improve the disease course during the 3 following years in this subset of patients.
Phase:
Phase 4
Details
Lead Sponsor:
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Collaborator:
Société Nationale Française de Gastroentérologie
Treatments:
Azathioprine
Immunosuppressive Agents
Methotrexate